ASCO: Component in green tea may help reduce prostate cancer in men at high risk
Polyphenon E reduced combined rates of prostate cancer and atypical small acinar proliferation rates, as well as decreased levels of prostate-specific antigen in men who have premalignant prostate lesions or high-grade intraepithelial neoplasia
2015-05-28
(Press-News.org) TAMPA, Fla. - Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer. A team of researchers led by Nagi B. Kumar, Ph.D., R.D., F.A.D.A. at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men who have premalignant lesions. The results will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Twenty percent of green tea is consumed in Asian countries where prostate cancer death rates are among the lowest in the world and the risk of prostate cancer appears to be increased among Asian men who abandon their original dietary habits upon migrating to the U.S.
Laboratory studies have shown that substances in green tea called, "catechins" inhibit cancer cell growth, motility and invasion, and stimulate cancer cell death. Green tea catechins also prevent and reduce tumor growth in animal models. Epigallocatechin-3-gallate (EGCG) is the most abundant and potent catechin found in green tea responsible for these cancer prevention effects.
The goal of this trial was to evaluate if a one-year intervention with green tea catechins could suppress prostate cancer development in men who had high-grade intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP). The researchers used decaffeinated green tea capsules called Polyphenon E that contained a mixture of catechins that predominantly contained EGCG at a dose of 200 mgs twice a day.
The researchers compared Polyphenon E in 49 men to placebo tablets in 48 men over a 1 year treatment period. Overall, the difference in the number of prostate cancer cases at the end of 1 year between the two treatment groups was not statistically significant. However, in men who only had HGPIN at the beginning of the trial, they observed a lower combined rate of ASAP and prostate cancer development with Polyophenon E. ASAP is an entity that reflects a broad group of lesions in the prostate with insufficient changes in the cells to be definitively diagnosed as prostate cancer. Additionally, men on Polyphenon E had a significant decrease in prostate-specific antigen (PSA) levels. PSA is a biomarker that in combination with other risk factors is used to screen patients for prostate cancer, and high levels signify a higher risk of prostate cancer.
The Moffitt researchers observed a significant increase in the levels of EGCG in the blood plasma of men on Polyphenon E, and the capsules at this dose were tolerated in this group of men.
The ASCO poster session will take place Monday, June 1, 1:15-4:45 p.m. in S Hall A. The study was published in the April 14 issue of the journal Cancer Prevention Research. Funding support was received from the National Institutes of Health/National Cancer Institute (R01 CA12060-01A1).
INFORMATION:
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report's "Best Hospitals" for cancer care since 1999. With more than 4,500 employees, Moffitt has an economic impact in Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.
ELSE PRESS RELEASES FROM THIS DATE:
2015-05-28
TAMPA, Fla. - Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. Preclinical studies suggest that JAK2 inhibitors may be an effective treatment option for CMML. Eric Padron, M.D., assistant member of the Malignant Hematology Program at Moffitt Cancer Center will report on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients ...
2015-05-28
TAMPA, Fla. - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
Nivolumab targets a protein called the programmed death-1 (PD-1) receptor. The ...
2015-05-28
Many living things can respond to electric fields, either moving or using them to detect prey or enemies. Weak electric fields may be important growth and development, and in wound healing: it's known that one of the signals that guides cells into a wound to repair it is a disturbance in the normal electric field between tissues. This ability to move in response to an electric field is called galvanotaxis or electrotaxis.
UC Davis dermatology professor Min Zhao, Peter Devroetes at Johns Hopkins University and colleagues hope to unravel how these responses work, studying ...
2015-05-28
Unstable funding is threatening the viability of academic biomedical research in this country, according to a new paper published this week in the journal Science Translational Medicine. The paper was written jointly by the deans of 19 prominent medical schools around the country. Among this group is University of Maryland School of Medicine Dean E. Albert Reece.
"We must reinvigorate the federal-academic partnership for research across all sciences," the authors write. If the current trends in funding continue, both established investigators and early-career scientists ...
2015-05-28
CHICAGO (May 28, 2015): Traumatic injury is the leading cause of death among people under age 45, but if trauma physicians could deliver plasma to these injury victims within minutes of their arrival in the emergency room, more of them would stand a better chance of survival.
When they arrive at the hospital, trauma victims can often wait 30 minutes or longer to receive plasma because the traditional way of giving them plasma involves two time-consuming steps: testing for blood type and then thawing frozen plasma. "There's a golden hour after trauma where you need to ...
2015-05-28
Using a complex modeling program that helps analyze the physical dynamics of large, structurally complex protein molecules, a research team has made progress towards finding a weak spot in the architecture of a group of enzymes that are essential to antibiotic resistance in a number of bacteria.
In an article published in PLOS ONE, University of North Carolina at Charlotte senior biology major Jenna R. Brown and her faculty mentor, UNC Charlotte professor of bioinformatics and genomics Dennis R. Livesay, present an analysis of the four currently known protein structures ...
2015-05-28
Immune cells play an important role in the upkeep and repair of our bodies, helping us to defend against infection and disease. Until now, how these cells detect a wounded or damaged site has largely remained a mystery. New research, led by University of Bristol academics in collaboration with a team from the University of Sheffield, has identified the triggers which lead these cells to react and respond in cell repair.
It is hoped the findings, published in Current Biology, could help scientists design therapies to manipulate the cell repair process and direct immune ...
2015-05-28
Flies might be smarter than you think. According to research reported in the Cell Press journal Current Biology on May 28, fruit flies know what time of day it is. What's more, the insects can learn to connect different scents with the sweet reward of sugar, depending on the hour: menthol in the morning and mushrooms in the afternoon.
Researchers say that the findings show the surprising mental abilities of animals, no matter how small.
"If even the fly, with its miniature brain, has the sense of time, most animals may have it," says Martin Heisenberg of Rudolf Virchow ...
2015-05-28
Controlling bacterial infections responsible for typhoid fever could dramatically reduce the risk of gallbladder cancer in India and Pakistan, according to a study published by Cell Press May 28th in Cell Host & Microbe. The findings establish for the first time the causal link between bacterial infection and gallbladder cancer, explaining why this type of cancer is rare in the West but common in India and Pakistan, where typhoid fever is endemic. Public policy changes inspired by this research could have an immediate impact on preventing a type of cancer that currently ...
2015-05-28
The chemical rapamycin is used clinically as an immunosuppressant and as an anti-cancer agent that works by inactivating a protein named TOR (Target Of Rapamycin). This protein is essential for the growth of normal cells, but is hyperactive in tumor cells. To be able to carry out its various growth-related tasks, TOR needs to assemble into one of two larger protein complexes named TORC1 and TORC2. Curiously, whereas TORC1 is inhibited by rapamycin, TORC2 is unaffected by this drug. The team of Robbie Loewith, professor in biology at the University of Geneva (UNIGE), Switzerland, ...
LAST 30 PRESS RELEASES:
[Press-News.org] ASCO: Component in green tea may help reduce prostate cancer in men at high risk
Polyphenon E reduced combined rates of prostate cancer and atypical small acinar proliferation rates, as well as decreased levels of prostate-specific antigen in men who have premalignant prostate lesions or high-grade intraepithelial neoplasia
